For specialist clinicians actively managing patients on cannabis-based products for medicinal use (CBPMs). Monitoring quality is the principal determinant of whether a CBPM trial reaches a defensible clinical conclusion or drifts into open-ended prescribing without an evidence base. This piece sets out a working framework for baseline assessment, titration, validated outcome measurement, review cadence and the red flags that should prompt taper or stop.
None of what follows substitutes for clinical judgement or the prescribing specialist’s responsibility under the GMC Specialist Register requirement. It is a structure that holds up to audit and to shared-care correspondence.
Baseline assessment: what to capture before the first prescription
A defensible CBPM record starts with a thorough baseline. The aim is to document the clinical justification, the risk profile, and the measurable starting point against which response will be judged.
Clinical history
- Primary indication, duration and severity. Not just “chronic pain” but the pattern, anatomical distribution, established diagnostic label where one exists, and prior investigations.
- Prior treatment pathway. Specific agents tried, doses reached, duration of trial, reason for discontinuation. The unlicensed-special framework requires the prescriber to demonstrate a special clinical need; “tried other things” is not adequate documentation.
- Comorbidities relevant to CBPM safety. Cardiovascular disease, hepatic and renal function, respiratory disease, current pregnancy or plans for pregnancy, history of cancer where relevant to drug-interaction profile.
- Mental health history. Current and prior diagnoses, current treatment, current symptom severity. Explicit screen for personal or first-degree family history of psychotic illness — this is the single most important screen for THC-containing products.
- Substance use history. Tobacco, alcohol units per week, cannabis (recreational or prior medicinal), other illicit substance use, current or past dependence.
Medication review
A full medication list including prescription, OTC, and supplements, screened against the interaction categories covered in our prescribers resources and in our companion piece on CBPM drug interactions. Flag warfarin, clobazam, transplant immunosuppressants, high-dose opioids, sedatives, SSRIs/SNRIs and CYP3A4 substrates explicitly.
Baseline investigations
- Liver function tests before initiation, particularly where high-dose CBD is anticipated or where co-medications include hepatotoxic agents. Repeat at 1 month, 3 months, then per clinical context.
- Renal function as part of standard baseline biochemistry, particularly where concurrent nephrotoxic agents are in use.
- Resting heart rate and blood pressure documented in clinic.
- ECG where indicated by cardiovascular history or co-medications.
Baseline outcome measures
This is where most CBPM records fall short. Validated patient-reported outcome (PRO) measures completed at baseline make every subsequent review meaningful. The appropriate instrument depends on the indication:
- Chronic pain: Brief Pain Inventory (BPI), short or long form. Captures pain severity and pain interference across daily activities. Visual analogue or numerical rating scales are acceptable as a minimum but BPI is more useful at follow-up.
- Anxiety: GAD-7 (Generalised Anxiety Disorder 7-item scale). Brief, validated, well-suited to repeated use.
- Depression: PHQ-9 (Patient Health Questionnaire 9-item). The standard primary-care depression measure; appropriate in CBPM monitoring for mental-health comorbidity.
- Combined anxiety and depression: HADS (Hospital Anxiety and Depression Scale). Useful where mood and anxiety symptoms are both present.
- PTSD: PCL-5 (PTSD Checklist for DSM-5) or, where the patient is already under trauma-focused care, the local service’s preferred measure.
- Sleep: Insomnia Severity Index (ISI) or Pittsburgh Sleep Quality Index (PSQI).
- Quality of life: EQ-5D-5L. The instrument used in Project Twenty21 and a sensible cross-indication measure.
- Palliative care: Edmonton Symptom Assessment Scale (ESAS). Designed for multi-symptom palliative review and adapts well to CBPM monitoring in this population.
The point of capturing baselines on validated instruments is not academic. At three months, when the patient and clinician are deciding whether to continue, taper or switch, the conversation is materially better when supported by quantified change rather than recall.
Titration principles: start low, go slow
The pharmacology of cannabinoids — non-linear dose-response, biphasic effects of THC, wide inter-patient variability — makes conservative titration not a courtesy but a clinical necessity. The “start low, go slow” maxim has been the consensus titration principle across UK and international CBPM practice since rescheduling.
Typical starting points (observational, not prescriptive)
The literature describes a wide range of starting doses across CBPM practice. We describe these as observational, not as recommendation:
- THC-containing oils: typical starting points in published registry and clinical literature are below 5 mg THC per day, often 1-2.5 mg, taken in the evening. Increments at 3-7 day intervals as tolerated.
- CBD-only oils: starting points more variable. For symptomatic indications, low- to mid-tens of mg per day are common starting ranges, with titration over weeks. Epilepsy doses are markedly higher and follow the licensed Epidyolex protocol.
- Inhaled flower: single-inhalation titration with very small per-inhalation doses, separated by intervals long enough to assess effect (typically 10-15 minutes).
The actual dose for any individual patient depends on indication, prior cannabis exposure, comorbidities, co-medications and tolerability. The clinical record should document the rationale for the starting dose, not just the dose itself.
Titration discipline
- One variable at a time. Avoid simultaneous changes in product, dose and formulation.
- Allow steady state. Oral preparations need 3-7 days at a new dose before meaningful assessment.
- Patient self-titration only within explicit prescribed limits and after the early titration phase is settled.
- Set a target effective dose with the patient. Continued upward titration without a defined goal drifts into open-ended escalation.
Review cadence in private specialist practice
UK private specialist CBPM practice has converged on a recognisable review pattern. Specific clinic protocols vary; the underlying structure is broadly:
Early titration phase (first 4-6 weeks)
Initial review at approximately 4 weeks after first dispense. Purpose: confirm tolerability, screen for unexpected adverse effects, refine titration, address adherence questions. Many clinics include a remote check-in at 1-2 weeks. PROs repeated; compare with baseline.
Stabilisation review (approximately 12 weeks)
A more substantive review at around 3 months. Purpose: determine whether the trial has produced meaningful benefit, decide on continuation, and document the clinical justification for ongoing prescribing. This is the point at which the structured baseline assessment pays off — PROs, function, medication changes (notably opioid reduction in chronic pain indications) and patient-reported quality of life are compared formally.
This is also the appropriate point to decide on shared-care arrangements, given that many UK GPs will only accept shared care once a patient is demonstrably stable.
Maintenance reviews (6 months and onwards)
Once stable, a typical cadence is 6-monthly review with the prescribing specialist. Some patients require more frequent review — those with mental-health comorbidity, those on complex polypharmacy, those at the upper end of dose range. Patients on very stable regimens may extend toward 12-monthly with appropriate safeguards. Each review should re-confirm continued indication, re-evaluate alternatives, re-screen for new co-medications and re-document driving and lifestyle counselling.
What “response” actually looks like
It is essential to define response in advance and to be honest at review about whether it has been achieved. Useful working definitions:
- Pain: a clinically meaningful improvement on BPI severity and interference scores (typically a 30% or greater reduction in pain severity is the threshold described in chronic pain literature), accompanied by stable or reduced concomitant analgesic use and functional improvement.
- Anxiety: a meaningful reduction in GAD-7 score (typically a 5-point or greater reduction or a category shift), with functional improvement.
- Depression: a meaningful reduction in PHQ-9, similarly.
- Sleep: a clinically meaningful reduction in ISI or PSQI plus patient-reported improvement.
- Quality of life: a measurable improvement on EQ-5D-5L. Project Twenty21 published data showed visual-analogue EQ-5D-5L improvement of Cohen’s d = 0.77 at 3 months in a registry population — a useful comparator for clinicians.
- Palliative: reduction in ESAS-measured symptom burden across the symptom domains for which the CBPM was started.
A patient who reports general benefit but whose PROs are unchanged is in a different position from a patient whose PROs have moved. Both findings warrant honest discussion; the second is a stronger case for continuation.
When to taper or stop
CBPM prescribing should not be open-ended. Clear stopping criteria, set out at initiation and revisited at review, protect both clinician and patient.
- No meaningful response at adequate dose and duration. If after 12 weeks at a titrated dose the PRO measures show no clinically meaningful change, the indication for continuing prescribing weakens substantially.
- Adverse effects outweighing benefit. Persistent sedation impacting function, cognitive impairment, mood deterioration, weight change, cardiovascular effects.
- New contraindication. Pregnancy, new psychotic symptoms, new cardiovascular event, severe hepatic deterioration.
- Signs of misuse or diversion. Repeated lost or early prescriptions, requests for escalating doses without proportionate clinical justification, evidence of supply outside the prescribing relationship.
- Loss of follow-up. Patients who repeatedly miss reviews cannot be safely maintained on Schedule 2 prescribing indefinitely.
Tapering, where appropriate, is usually well tolerated; cannabinoid withdrawal symptoms (irritability, sleep disturbance, appetite changes) are typically mild compared with opioid or benzodiazepine withdrawal but can be uncomfortable and warrant a structured taper schedule rather than abrupt discontinuation.
Red flags during ongoing management
- New or worsening psychiatric symptoms, particularly suspiciousness, perceptual disturbance, severe anxiety, dissociation, or deterioration in baseline mood disorder. Suspend or reduce, and arrange mental-health input.
- Sedation impacting function. Falls in older patients, near-miss driving incidents, impaired performance at work. Reduce dose, review co-medications, consider formulation switch.
- Paradoxical worsening of the index symptom. Pain that escalates rather than improves on CBPM, anxiety that worsens at higher THC doses. Often a sign of biphasic dose-response; trial a dose reduction before escalation.
- Cardiovascular events in patients on THC-containing products. Reassess fitness for continued THC exposure.
- Hepatic transaminase elevation in patients on high-dose CBD, particularly those on valproate. Reduce dose, repeat LFTs, consider switch.
- Signs of dependence or compulsive use, particularly in patients with a substance-use history. Re-engage addictions services.
Communication with primary care
The quality of the specialist-to-GP relationship is one of the most under-rated determinants of safe CBPM management. A patient on Schedule 2 prescribing by a private specialist often has the majority of their other medicines prescribed in NHS primary care. Without good communication, new medicines get added without interaction screening, dose changes happen in parallel, and the patient is left mediating between two prescribers.
At minimum, the prescribing specialist should send a structured letter to the GP at initiation, at any major change in regimen, and at each formal review. The letter should make clear what the GP is being asked to do (typically: not prescribe the CBPM, but flag any new co-medication considerations to the specialist) and what the GP is not being asked to do.
Documentation: the controlled drug register and patient record
CBPMs sit under Schedule 2 of the Misuse of Drugs Regulations 2001 (as amended November 2018). Standard Schedule 2 controlled drug register requirements apply at dispensing pharmacies: separate entries for each receipt and supply, with patient identifier, quantity, date, and the prescriber’s details. Reconciliation at each dispense is expected practice.
In the clinical record, each review should document: current regimen; PRO scores with comparison to baseline; adverse effects since last review; medication changes since last review; new co-medications screened; ongoing indication confirmed; plan to next review. For the supply-chain logistics underpinning consistent dispense, see our piece on CBPM supply chain considerations.
A short ongoing-management checklist
- Baseline PROs completed before first prescription.
- Initial review at 4 weeks with PROs repeated.
- Stabilisation review at 12 weeks with explicit continue/taper decision.
- Maintenance reviews at 6-monthly intervals (more often if comorbidity warrants).
- Shared-care letter at initiation and updates at each major change.
- Defined stopping criteria set at initiation and revisited at every review.
- Driving advice re-issued at every dose change.
- CD register reconciliation at every dispense.
For broader context on where CBPMs are most often considered in UK specialist practice, see our companion overview on the UK specialist prescribing pathway.
About MUZO Health
MUZO Health was created to raise the standard of cannabis-based medicines in the UK, with a focus on quality, consistency and clinical integrity. Our mission is to support clinicians, empower patients and help move cannabis medicine forward responsibly, transparently and without compromise. Learn more about MUZO Health.